Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMadhu Bhargavi Chandra

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows CAR-T reduces all-cause mortality in relapsed multiple myeloma, indicating severe acute toxicities persist.

Key Points

  • This study aims to compare the real-world outcomes of CAR-T therapy and pomalidomide-based regimens in patients with relapsed/refractory multiple myeloma.
  • Retrospective cohort study using TriNetX network
  • Propensity score matching of 437 patients each for CAR-T and pomalidomide
  • Assessment of clinical outcomes over 12 months post-treatment
  • Use of Kaplan-Meier analysis and hazard ratios for efficacy and safety analyses
  • CAR-T therapy resulted in lower all-cause mortality compared to pomalidomide (HR 0.63)
  • Higher hospitalization risk associated with CAR-T (HR 4.49)
  • Increased risk of cytokine release syndrome with CAR-T (HR 12.70)
  • Greater incidence of neutropenia after CAR-T (HR 1.94)
  • CAR-T reduced pneumonia risk (HR 0.57)

Cite This Study

Madhu Bhargavi Chandra (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d168https://doi.org/10.1182/blood-2025-5849
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (<70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study2025
  2. 2Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  3. 3Thromboembolic and cardiovascular events after CAR-T cell therapy in multiple myeloma: A propensity-matched real-world analysis2025
  4. 4Comparative real-world outcomes of bispecific antibodies versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort analysis2025
  5. 5Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses2025